| Literature DB >> 35444752 |
Sandra L Jaimes1, Carlos E Ramírez1, Andres F Viviescas2, Andres F Abril2, David F Flórez2, Cristian D Sosa2.
Abstract
Introduction Burn wound infection (BWI) is the second most important cause of death in burn patients. There is currently limited data about the incidence and clinical presentation of BWI using quantitative techniques as quantitative biopsy culture (QBC) to prevent progress to burn wound sepsis (BWS). Methods This is a prospective cohort study of patients diagnosed with BWI, confirmed by QBC, from February 2018 to July 2019 at University Hospital of Santander (HUS). The primary outcome was to determine clinical, microbiological, and histopathological characteristics of patients diagnosed with BWI along with a positive QBC and their relationship with early diagnosis and progression to BWS. Results 525 patients were admitted to HUS Burn Center. Of those, 44/525 (8.23%) presented a clinical diagnosis of BWI (median age, 20.5 years [1-67 years]; 25/44 [56.8%] male). QBC was positive in 26/44 (59%), Staphylococcus aureus 14/44 (31.8%), and Pseudomonas aeruginosa 7/44 (15.9%) were the mainly etiological agents isolated. Bacterial resistance to antibiotics was mostly to beta-lactams in 14/44 (31.8%), corresponding to methicillin-resistant Staphylococcus aureus (MRSA). Clinical signs more related to infection were erythema in 33/44 (61.3%). As many as 10/44 (22.7%) progressed to sepsis and 2/44 (6%) died. Conclusion BWI increases hospitalization time and number of surgeries, increasing the risk of sepsis and death. The QBC allows an accurate diagnosis with lesser false-positive cases that impact antibiotic resistance and mortality. Protocols targeting this problem are needed to decrease the impact of this. Association of Plastic Surgeons of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: Burn Wound; Burn Wound Infection; Burn Wound Sepsis; Quantitative Biopsy Culture
Year: 2022 PMID: 35444752 PMCID: PMC9015825 DOI: 10.1055/s-0041-1740494
Source DB: PubMed Journal: Indian J Plast Surg ISSN: 0970-0358
Sociodemographic and clinical characteristics
| Sociodemographic and clinical characteristics |
| % | CI 95% |
|---|---|---|---|
|
| |||
| Female | 19 | 43.2 | 27.9–58.4 |
| Male | 25 | 56.8 | 41.6–72.1 |
|
| |||
| Pediatric (under 18 years) | 17 | 38.6 | 23.7–53.6 |
| Adult (above18 years) | 27 | 61.4 | 46.4–76.3 |
|
| |||
| No | 30 | 68.2 | 53.9–82.5 |
| Yes | 14 | 31.8 | 17.5–46.1 |
|
| |||
| Scalds | 24 | 54.6 | 39.2–69.9 |
| Direct contact | 18 | 40.9 | 25.8–56.0 |
| Electric | 2 | 4.5 | 0.0–10.9 |
|
| |||
| Second degree | 32 | 72.7 | 59.0-86.4 |
| Third degree | 12 | 27.3 | 13.6–41.0 |
|
| |||
| Minor (less than 20% TBSA adults or 10% in children) | 25 | 56.8 | 41.6–72.1 |
| Major (above those percentages) | 19 | 43.2 | 27.9–58.4 |
|
| |||
| Upper limb | 32 | 72.7 | 59.0–86.4 |
| Lower limb | 28 | 63.6 | 48.8–78.4 |
| Head and neck | 27 | 61.4 | 46.4–76.3 |
| Anterior torso | 18 | 40.9 | 25.8–56.0 |
| Posterior torso | 12 | 27.3 | 13.6–41.0 |
|
| |||
| Erythema | 33 | 75.0 | 61.7–88.3 |
| Edema | 27 | 61.4 | 46.4–76.3 |
| Exudate | 20 | 45.5 | 30.1–60.8 |
| Eschar discoloration | 15 | 34.1 | 19.5–48.7 |
| Pain increasing | 9 | 20.5 | 8.0–32.9 |
| Separation of eschar | 7 | 15.9 | 4.7–27.2 |
| Loss of skin grafts | 1 | 2.3 | 0.0–6.9 |
| Lymphangitis | 1 | 2.3 | 0.0–6.9 |
Abbreviations: CI, confidence interval; TBSA, total body surface area.
HUS Bucaramanga 2017–2018.
Chi-Square Test (or Fisher's Test)
Clinical evolution
| Clinical evolution |
| % | CI 95% |
|---|---|---|---|
|
| |||
| Early-onset (before 72 hours) | 41 | 93.2 | 85.4–100.0 |
| Late-onset (after 72 hours) | 3 | 6.8 | 0.0–14.6 |
|
| |||
| No | 17 | 38.6 | 23.7–53.6 |
| Yes | 27 | 61.4 | 46.4–76.3 |
|
| |||
| No | 3 | 6.8 | 0.0–14.6 |
| Yes | 38 | 86.4 | 75.8–96.9 |
| Not reported | 3 | 6.8 | 0.0–14.6 |
|
| |||
| No | 6 | 13.6 | 3.1–24.2 |
| Yes | 38 | 86.4 | 75.8–96.9 |
|
| |||
| No | 13 | 29.6 | 15.5–43.6 |
| Yes | 31 | 70.4 | 56.4–84.5 |
|
| |||
| No | 32 | 72.7 | 59.0–86.4 |
| Yes | 12 | 27.3 | 13.6–41.0 |
|
| |||
| No | 41 | 95.4 | 88.8–100.0 |
| Yes | 2 | 4.6 | 0.0–11.2 |
Abbreviations: CI, confidence interval; n , number.
HUS Bucaramanga 2017–2018
Chi-Square Test (or Fisher's Test)
Histopathological findings
| Histopathological findings |
| % | CI 95% |
|---|---|---|---|
|
| |||
| Superficial | 6 | 13.6 | 3.1–24.2 |
| Deep | 5 | 11.4 | 1.6–21.1 |
| Not determined | 33 | 75.0 | 61.7–88.3 |
|
| |||
| I | 2 | 4.6 | 0.0–10.9 |
| I A | 0 | 0.0 | – |
| I B | 2 | 4.6 | 0.0–10.9 |
| II | 6 | 13.6 | 3.1–24.2 |
| II A | 5 | 11.4 | 1.6–21.1 |
| II B | 7 | 15.9 | 4.7–27.2 |
| II C | 9 | 20.5 | 8.0–32.9 |
| Not observed | 13 | 29.6 | 15.5–43.6 |
|
| |||
|
| 14 | 31.8 | 17.5–46.1 |
|
| 7 | 15.9 | 4.7–27.2 |
|
| 3 | 6.8 | 0.0–14.6 |
|
| 2 | 4.6 | 0.0–10.9 |
|
| 2 | 4.6 | 0.0–10.9 |
|
| 1 | 2.3 | 0.0–6.9 |
|
| 1 | 2.3 | 0.0–6.9 |
|
| 1 | 2.3 | 0.0-6.9 |
|
| 1 | 2.3 | 0.0–6.9 |
|
| 1 | 2.3 | 0.0–6.9 |
|
| 1 | 2.3 | 0.0–6.9 |
| Fungi | 1 | 2.3 | 0.0–6.9 |
| Other | 1 | 2.3 | 0.0–6.9 |
|
| |||
| Beta-lactams | 14 | 31.8 | 17.5–46.1 |
| Carbapenems | 2 | 4.6 | 0.0–10.9 |
| Aminoglycosides | 1 | 2.3 | 0.0–6.9 |
| Lincosamides | 2 | 4.6 | 0.0–10.9 |
| Quinolones | 3 | 6.8 | 0.0–14.6 |
| Sulfonamides | 7 | 15.9 | 4.7–27.2 |
| Ureidopenicillins | 1 | 2.3 | 0.0–6.9 |
HUS Bucaramanga 2017–2018.
Bivariate analysis of sociodemographic and clinical characteristics and signs of infection
| Sociodemographic and clinical variables |
| No infection | Infection | OR | CI | |
|---|---|---|---|---|---|---|
|
| ||||||
| Female | 19 | 42.1 | 57.9 | |||
| Male | 25 | 36.0 | 64.0 | 1.29 | 0.31–5.18 | 0.680 |
|
| ||||||
| Pediatric | 17 | 41.2 | 58.8 | |||
| Adult | 27 | 37.0 | 63.0 | 1.19 | 0.28–4.85 | 0.784 |
|
| ||||||
| No | 30 | 36.7 | 63.3 | |||
| Yes | 14 | 42.9 | 57.1 | 0.77 | 0.17–3.49 | 0.694 |
|
| ||||||
| Scalds | 24 | 37.5 | 62.5 | |||
| Direct contact | 18 | 44.4 | 55.6 | |||
| Electrical | 2 | 0.0 | 100.0 | 0.9 | 0.22–3.61 | 0.865 |
|
| ||||||
| Second degree | 32 | 46.9 | 53.1 | |||
| Third degree | 12 | 16.7 | 83.3 | 4.41 | 0.73–46.3 | 0.066 |
|
| ||||||
| Minor | 25 | 44.0 | 56.0 | |||
| Major | 19 | 31.6 | 68.4 | 1.70 | 0.41–7.28 | 0.402 |
|
| ||||||
| A single affected anatomical area | 15 | 40.0 | 60.0 | |||
| More than one affected anatomical area | 29 | 37.9 | 62.1 | 1.09 | 0.24–4.62 | 0.894 |
|
| ||||||
| Erythema | 33 | 33.3 | 66.7 | 2.4 | 0.47–12.2 | 0.210 |
| Edema | 27 | 33.3 | 66.7 | 1.77 | 0.42–7.32 | 0.363 |
| Exudate | 20 | 35.0 | 65.0 | 1.32 | 0.33–5.43 | 0.651 |
| Eschar discoloration | 15 | 40.0 | 60.0 | 0.91 | 0.21–4.06 | 0.894 |
| Pain increasing | 9 | 44.4 | 55.6 | 0.73 | 0.13–4.46 | 0.688 |
| Separation of eschar | 7 | 40.0 | 60.0 | 4.57 | 0.46–223,1 | 0.894 |
| Loss of skin grafts | 1 | 100.0 | 0.0 | – | – | – |
| Lymphangitis | 1 | 100.0 | 0.0 | – | – | – |
Abbreviations: CI, confidence interval; OR, odds ratio.
HUS Bucaramanga 2017–2018.
Test chi cuadrado (o Fisher).